Antigen presentation
Dendritic cells help convert tumor-derived information into productive immune activation.
MIORG focuses on the biology behind checkpoint therapy response and resistance, with particular attention to immune function, patient stratification, and the role of dendritic cells in generating effective antitumor T-cell responses.
Checkpoint therapy response prediction, dendritic-cell-centered resistance biology, rational combinations, and translational validation.
Anti-PD1 and anti-PD-L1 therapies changed the treatment landscape by enabling durable responses in selected patients across multiple tumor types. These agents remain among the most consequential advances in immuno-oncology and continue to shape how modern cancer treatment is designed.
Checkpoint therapy created a new therapeutic foundation, but it also exposed a persistent problem: powerful treatments still require better prediction and better combination logic to serve more patients.
A meaningful proportion of patients do not respond to checkpoint blockade. Existing tools such as immunohistochemistry markers and tumor mutational burden can offer partial signal, but they may not be sufficient on their own for confident patient selection or clinical planning.
MIORG frames resistance as a tractable biological and translational problem.
Dendritic cells are central to antigen presentation and to the generation of new antitumor T-cell responses. When tumors suppress these processes, checkpoint inhibition alone may be insufficient. MIORG’s therapeutic thinking therefore centers on restoring or protecting critical antigen-presenting function in resistant settings.
Dendritic cells help convert tumor-derived information into productive immune activation.
New antitumor T-cell responses are essential for durable immune control in resistant settings.
MIORG’s antibody strategy is designed to restore this pathway in combination-oriented development.
Response prediction benefits from a multidimensional view of tumor and immune context. MIORG’s predictive profiling approach is designed around immune functional RNA/DNA profiling, integrating a focused immune-related gene signature with tumor mutational burden to improve response prediction for anti-PD1/PD-L1 therapies.
Predictive profiling is positioned not as an isolated dataset exercise, but as a tool for real-world oncology decision support and partnership-led development.
Combination development in immuno-oncology is strongest when it follows mechanism. MIORG’s therapeutic programs are shaped around the biology of immune resistance, particularly where dendritic-cell impairment may limit the impact of checkpoint blockade alone.
Programs are designed to complement checkpoint therapy rather than simply add another agent.
Development emphasis is on resistant tumor models and careful mechanistic interpretation.
Combination candidates can align with broader biomarker, translational, and co-development discussions.
Define resistance mechanisms, immune signatures, and tractable intervention points.
Use biologically grounded assays to test immune activity, dendritic cell function, and combination logic.
Evaluate programs in resistant tumor contexts to refine development and partnering hypotheses.
Translate insights into patient stratification, validation pathways, and collaboration-ready programs.